patients receiving 45 mg and 76.9% of those receiving 90 mg experienced a reduction of 5 points in DLQI score, signifying an important difference, compared with 21.4% for placebo (each p < 0.001 versus placebo). All DLQI scores improved from baseline to Week 12 in each active treatment group compared with placebo (each p < 0.001 versus placebo). Improvements were observed in clinical parameters, HADS, and WLQ. CONCLUSION: Ustekinumab resulted in significant and clinically meaningful improvements in QOL within 1 month after starting treatment; improvements at Week 12 were maintained through Week 24. Improvements were also observed in anxiety, depression, and work limitations.
PSS31 ASSESSMENT OF QUALITY OF LIFE IN DAILY CLINICAL DERMATOLOGICAL ROUTINE: QUESTIONNAIRES AND CHECKLIST
Tabolli S 1 , Abeni D 2 , Di Pietro C 2 , Sampogna F 2 1 IDI IRCCS, ROME, Italy, 2 IDI IRCCS, Rome, Italy OBJECTIVE: Patient-reported outcome measures, in particular those evaluating health-related quality of life (HrQoL) , have been proposed as a mean of facilitating doctor-patient communication. While these measures are commonly included in clinical research studies, their use in clinical practice is still quite limited. Our objective is to assess HrQoL in a dermatological clinic daily routine and to develop an appropriate and effective reporting tool for health personnel. METHODS: First phase: patients were invited to complete the Skindex-29, GHQ-12, and SF-36 questionnaires. Scores were returned to the clinical staff. Second phase: the patients' medical records were reviewed to verify which issues (e.g., pain, itch, bleeding, sleep loss, functional limitations, fatigue) highlighted by the questionnaires were recorded/neglected by physicians. Third phase: we developed a check list (presence/absence) of symptoms, emotions or functional problems to be filled by health personnel to complete the routine clinical records. RESULTS: For 170 participants (63% males, 35% age > 64 years), feedback forms were provided within three hours from data collection. We analyzed data for 126 patients with the most common conditions: psoriasis (n = 40), dermatitis (n = 30), leg ulcers (n = 13), pemphigus (n = 22), cutaneous lymphoma (n = 21). Overall, sensitivity of medical records in identifying patients' problems ranged from zero for most issues (including sleep loss, sex life, bleeding), to 3% for burning, 10% for depression, 15% for pain, and 35% for itching. A 30-item checklist (a synthesis of the three questionnaires) was developed and tested in 100 patients who completed their Skindex-29 questionnaire. The sensitivity and specificity of physicians' records increased for each issue, ranging from 7% (humiliation) to 81% (itching). CONCLUSION: The routine assessment of HrQoL in dermatology is feasible. The checklist induced the staff to report on medical records often-neglected patients' problems. The checklist increased substantially the sensitivity of physicians in identifying patients' problems.
PSS32 QUALITY OF LIFE AND PSYCOLOGICAL DISTRESS IN PATIENT WITH CUTANEUOS LYMPHOMA
Sampogna F 1 , Frontani M 1 , Baliva G 1 , Russo G 1 , Di Pietro C 1 , Abeni D 1 , Tabolli S 2 1 IDI IRCCS, Rome, Italy, 2 IDI IRCCS, ROME, Italy OBJECTIVE: Cutaneous lymphomas may have a profound impact on patients' health-related quality of life (HRQoL) and psychological well-being. A detailed investigation of HRQoL, analyzing its correlation with clinical variables and biological parameters, has not been done before. METHODS: The study population consisted of patients with cutaneous T-cell (CTCL) or B-cell lymphoma (CBCL), consecutively recruited in the outpatient and the inpatient clinics of an Italian hospital. Data was collected using a dermatology-specific questionnaire, the Skindex-29 (symptoms, emotions, and functioning scales), and an oncology-specific questionnaire, the EORTC QLQ-C30 (15 scales, concerning physical and emotional aspects). RESULTS: Of 95 patients, there were 24 patients with CBCL, 59 with mycosis fungoides (MF), and 12 with Sézary syndrome (SS). The most frequent problems appearing from the EORTC QLQ-C30 analysis were fatigue, pain, and insomnia. The differences among hystotypes were particularly high in the global health status and emotional functioning scales, with a worse HRQoL in patients with SS, followed by MF, and CBCL. HRQoL impairment in all hystotypes was higher in women than in men, in patients with probable anxiety or depression, and when the disease worsened. The multivariate analysis of the independent role of each variable confirmed these results. The highest prevalence of probable anxiety or depression was observed in patients treated with systemic steroids (60%) and interferon (50%). CONCLUSION: The detailed evaluation of HRQoL and psychological problems in patients with cutaneous lymphomas, and their relationship with clinical variables, may give important information on the course of the disease as well as the possible effect of treatment.
PSS33 INTERNATIONAL DEVELOPMENT OF THE FIRST QUALITY OF LIFE INSTRUMENT SPECIFIC TO COSMETOLOGY AND PHYSICAL APPEARANCE:THE BEAUTYQOL INITIATIVE
Beresniak A 1 , Auquier P 2 , Duru G 3 , Krueger GG 4 , Talarico S 5 , Tsutani K 6 , De Linares Y 7 , Berger G 8 1 Data Mining International, Geneva, Switzerland, 2 Laboratoire de Santé Publique, Marseilles, France, 3 National Centre of Scientific Research, Lyon, France, 4 School of medicine, S.L.C, UT, USA, 5 Federal University of Sao Paulo, Sao Paulo, Brazil, 6 Tokyo University, Tokyo, Japan, 7 L'Oréal International, Asnieres sur Seine, France, 8 University Pierre&Marie Curie, Paris, France OBJECTIVE: To develop an internationally validated Quality of Life (QoL) instrument specific to cosmetology and personal appearance. This instrument will allow to measure the impact of the use of cosmetic products in various QoL dimensions. METHODS: Several studies have demonstrated the positive impact of cosmetic products in dimensions. However, no specific instrument exists to assess the main QoL dimensions in the general population of cosmetic users. The BeautQol questionnaire is designed to be a multi-dimensional, self-administered QoL questionnaire developed simultaneously in 13 countries. The questionnaire focuses on concerns identified by users using cosmetic products or cosmetic techniques. Semi directive interviews were carried out simultaneously in 10 countries with a total of 309 users by clinical psychologists in France (32), UK (18), Germany (46), Spain (27), Sweden (19), Russia (16), USA (53), Brazil (32), Japan (48), and China (18). Interviews have been audio or video recorded and reported in a standard format report. Interviews were analyzed both semantically and using text-mining techniques (Alceste software). RESULTS: From the analysis of the 10 interview country reports, 61 items were selected leading to 61 questions in the prototype questionnaire describing major domains such as well being, self esteem, social life, love life, sexual life, confidence, happiness, image, status, emotion, seduction, success, vitality, charisma, motivation, joy, fun, dignity, etc. Three additional countries joined the project (India, South Africa and Italy). The acceptability study is currently in progress with 650 users. The planned validation study A294 Abstracts
